Cargando…
P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS
BACKGROUND AND AIMS: Clinical course of Covid-19 is not yet established in autoimmune hepatitis (AIH). About 25% of our 400 AIH-outpatients from various states in Brazil are using hydrochloroquine (HCQ) for maintenance or treatment with corticosteroids and immunosuppressants (IS). The aim is to desc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468375/ http://dx.doi.org/10.1016/j.aohep.2021.100466 |
_version_ | 1784573651431981056 |
---|---|
author | Fadini Margon, Julia Raddatz Reis Vilela, Monique Damasio Moutinho, Bruna Rodrigues de Figueiredo, Sabrina Mitiko Deguti, Marta Benedita Terrabuio, Débora Raquel Rachid Cançado, Eduardo Luiz |
author_facet | Fadini Margon, Julia Raddatz Reis Vilela, Monique Damasio Moutinho, Bruna Rodrigues de Figueiredo, Sabrina Mitiko Deguti, Marta Benedita Terrabuio, Débora Raquel Rachid Cançado, Eduardo Luiz |
author_sort | Fadini Margon, Julia |
collection | PubMed |
description | BACKGROUND AND AIMS: Clinical course of Covid-19 is not yet established in autoimmune hepatitis (AIH). About 25% of our 400 AIH-outpatients from various states in Brazil are using hydrochloroquine (HCQ) for maintenance or treatment with corticosteroids and immunosuppressants (IS). The aim is to describe the clinical features and outcomes of COVID-19 in patients with AIH. METHODS: The diagnosis of COVID was confirmed by positive PCR of nasal swab and/or by serological tests. The diagnosis and treatment of COVID was not always made in our service. RESULTS: 33 patients, 85% female, 41±13yr; 88% AIH-1; 54.6% with advanced fibrosis (F3/F4); 81.8% with comorbidities (17 overweight/obesity [BMI 31.8±5.4], 10 arterial hypertension, 8 diabetes, 2 systemic lupus erythematosus [SLE, with renal failure], 1 celiac disease and malnutrition). The most frequent symptoms were cough (20), headache (19), anosmia and myalgia (18), diarrhea (17) and dyspnea (11). IS at infection was 14 azathioprine(AZA)+prednisone(PD), 2 AZA+PD+cyclosporine, 3 Mycophenolate+PD. HCQ was used for maintenance (6) or as a complement of IS (5). Five hospitalized patients received oxygen supplementation (1 endotracheal intubation); 1 was pregnant and 1 received methylprednisolone pulse+immunoglobulin to treat SLE immediately before COVID; 3 were under double IS and 2 HCQ. 23 received antibiotics (19 azithromycin). In 10 patients (9 with normal liver enzymes before COVID) there were IS adjustments: IS withdrawal and increase of PD dosage (6), increase PD dosage (2), IS withdrawal and HCQ prescription (1), AZA withdrawal+decrease PD dose (1). Six of the 10 patients had slight increase of liver enzymes, none liver decompensation. One patient died, with celiac disease who acquired COVID during hospitalization for lymphoma investigation. CONCLUSIONS: It appears that patients under IS for AIH and COVID-19 show outcomes similar to that of non-immunosuppressed population. HCQ does not appear to have a positive impact on preventing or progressing the disease. |
format | Online Article Text |
id | pubmed-8468375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier España, S.L. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84683752021-09-27 P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS Fadini Margon, Julia Raddatz Reis Vilela, Monique Damasio Moutinho, Bruna Rodrigues de Figueiredo, Sabrina Mitiko Deguti, Marta Benedita Terrabuio, Débora Raquel Rachid Cançado, Eduardo Luiz Ann Hepatol Article BACKGROUND AND AIMS: Clinical course of Covid-19 is not yet established in autoimmune hepatitis (AIH). About 25% of our 400 AIH-outpatients from various states in Brazil are using hydrochloroquine (HCQ) for maintenance or treatment with corticosteroids and immunosuppressants (IS). The aim is to describe the clinical features and outcomes of COVID-19 in patients with AIH. METHODS: The diagnosis of COVID was confirmed by positive PCR of nasal swab and/or by serological tests. The diagnosis and treatment of COVID was not always made in our service. RESULTS: 33 patients, 85% female, 41±13yr; 88% AIH-1; 54.6% with advanced fibrosis (F3/F4); 81.8% with comorbidities (17 overweight/obesity [BMI 31.8±5.4], 10 arterial hypertension, 8 diabetes, 2 systemic lupus erythematosus [SLE, with renal failure], 1 celiac disease and malnutrition). The most frequent symptoms were cough (20), headache (19), anosmia and myalgia (18), diarrhea (17) and dyspnea (11). IS at infection was 14 azathioprine(AZA)+prednisone(PD), 2 AZA+PD+cyclosporine, 3 Mycophenolate+PD. HCQ was used for maintenance (6) or as a complement of IS (5). Five hospitalized patients received oxygen supplementation (1 endotracheal intubation); 1 was pregnant and 1 received methylprednisolone pulse+immunoglobulin to treat SLE immediately before COVID; 3 were under double IS and 2 HCQ. 23 received antibiotics (19 azithromycin). In 10 patients (9 with normal liver enzymes before COVID) there were IS adjustments: IS withdrawal and increase of PD dosage (6), increase PD dosage (2), IS withdrawal and HCQ prescription (1), AZA withdrawal+decrease PD dose (1). Six of the 10 patients had slight increase of liver enzymes, none liver decompensation. One patient died, with celiac disease who acquired COVID during hospitalization for lymphoma investigation. CONCLUSIONS: It appears that patients under IS for AIH and COVID-19 show outcomes similar to that of non-immunosuppressed population. HCQ does not appear to have a positive impact on preventing or progressing the disease. Published by Elsevier España, S.L. 2021-09 2021-09-26 /pmc/articles/PMC8468375/ http://dx.doi.org/10.1016/j.aohep.2021.100466 Text en Copyright © 2021 Published by Elsevier España, S.L. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Fadini Margon, Julia Raddatz Reis Vilela, Monique Damasio Moutinho, Bruna Rodrigues de Figueiredo, Sabrina Mitiko Deguti, Marta Benedita Terrabuio, Débora Raquel Rachid Cançado, Eduardo Luiz P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title | P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title_full | P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title_fullStr | P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title_full_unstemmed | P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title_short | P-106 COVID-19 PRESENTATION AND OUTCOMES IN 33 PATIENTS WITH AUTOIMMUNE HEPATITIS |
title_sort | p-106 covid-19 presentation and outcomes in 33 patients with autoimmune hepatitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468375/ http://dx.doi.org/10.1016/j.aohep.2021.100466 |
work_keys_str_mv | AT fadinimargonjulia p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT raddatzreisvilelamonique p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT damasiomoutinhobruna p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT rodriguesdefigueiredosabrina p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT mitikodegutimarta p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT beneditaterrabuiodeboraraquel p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis AT rachidcancadoeduardoluiz p106covid19presentationandoutcomesin33patientswithautoimmunehepatitis |